Clinical trial
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
NCT06532006 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
- Lead sponsor
- Shanghai Henlius Biotech
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 22, 2024
- Completion date
- September 1, 2028
- Enrollment
- 550 (estimated)
- Sites
- 208
Conditions
As the registry lists them; a condition with its own page is linked.
gastric cancer, gastroesophageal-junction cancer, her2-positive gastric cancer, monoclonal antibody